VHCP Management as of Sept. 30, 2016
Portfolio Holdings for VHCP Management
VHCP Management holds 24 positions in its portfolio as reported in the September 2016 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Dbv Technologies (DBVTF) | 31.9 | $33M | 457k | 71.12 | |
Heron Therapeutics (HRTX) | 18.6 | $19M | 1.1M | 17.23 | |
Coherus Biosciences (CHRS) | 8.1 | $8.2M | 306k | 26.78 | |
Flamel Technologies | 6.1 | $6.2M | 500k | 12.40 | |
Adverum Biotechnologies | 4.5 | $4.5M | 1.1M | 4.11 | |
BioCryst Pharmaceuticals (BCRX) | 4.4 | $4.4M | 1.0M | 4.41 | |
Lipocine | 3.7 | $3.8M | 850k | 4.46 | |
Colucid Pharmaceuticals | 2.6 | $2.6M | 68k | 38.14 | |
Axovant Sciences | 2.5 | $2.6M | 184k | 14.00 | |
Ocera Therapeutics | 2.2 | $2.3M | 857k | 2.64 | |
Zafgen | 2.0 | $2.0M | 602k | 3.31 | |
Ascendis Pharma A S (ASND) | 1.8 | $1.8M | 90k | 20.10 | |
Alcobra | 1.6 | $1.6M | 659k | 2.47 | |
Beigene | 1.5 | $1.6M | 51k | 30.80 | |
D Stemline Therapeutics | 1.4 | $1.5M | 135k | 10.83 | |
Achillion Pharmaceuticals | 1.4 | $1.5M | 180k | 8.10 | |
Edge Therapeutics | 1.4 | $1.4M | 135k | 10.41 | |
Akari Therapeutics | 1.3 | $1.3M | 158k | 8.51 | |
ARCA biopharma | 1.3 | $1.3M | 462k | 2.83 | |
Cytomx Therapeutics (CTMX) | 1.0 | $1.0M | 64k | 15.69 | |
Regenxbio Inc equity us cm (RGNX) | 0.3 | $337k | 24k | 13.99 | |
Audentes Therapeutics | 0.3 | $267k | 15k | 17.80 | |
Pronai Therapeutics | 0.1 | $102k | 56k | 1.82 | |
Aeglea Biotherapeutics | 0.0 | $38k | 6.0k | 6.33 |